CY1115544T1 - Σκευασμα καψουλων πιρφενιδονης και αποδεκτων φαρμακευτικως εκδοχων - Google Patents
Σκευασμα καψουλων πιρφενιδονης και αποδεκτων φαρμακευτικως εκδοχωνInfo
- Publication number
- CY1115544T1 CY1115544T1 CY20141100731T CY141100731T CY1115544T1 CY 1115544 T1 CY1115544 T1 CY 1115544T1 CY 20141100731 T CY20141100731 T CY 20141100731T CY 141100731 T CY141100731 T CY 141100731T CY 1115544 T1 CY1115544 T1 CY 1115544T1
- Authority
- CY
- Cyprus
- Prior art keywords
- capsules
- pirphenidony
- experiences
- packaging
- pharmaceutical
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title abstract 2
- 238000004806 packaging method and process Methods 0.000 title 1
- 239000007963 capsule composition Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 abstract 2
- 229960003073 pirfenidone Drugs 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72025705P | 2005-09-22 | 2005-09-22 | |
| EP06815221.4A EP1940364B2 (en) | 2005-09-22 | 2006-09-22 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115544T1 true CY1115544T1 (el) | 2017-01-04 |
Family
ID=37898745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100731T CY1115544T1 (el) | 2005-09-22 | 2014-09-10 | Σκευασμα καψουλων πιρφενιδονης και αποδεκτων φαρμακευτικως εκδοχων |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US7988994B2 (https=) |
| EP (2) | EP1940364B2 (https=) |
| JP (3) | JP5837732B2 (https=) |
| KR (3) | KR20080046673A (https=) |
| CN (3) | CN103393607A (https=) |
| AP (2) | AP2012006231A0 (https=) |
| AU (2) | AU2006295440B2 (https=) |
| BR (1) | BRPI0616324A2 (https=) |
| CA (2) | CA2762013C (https=) |
| CU (1) | CU20080043A7 (https=) |
| CY (1) | CY1115544T1 (https=) |
| DK (1) | DK1940364T4 (https=) |
| EA (1) | EA030093B1 (https=) |
| EC (1) | ECSP088394A (https=) |
| ES (1) | ES2496144T5 (https=) |
| GE (1) | GEP20115303B (https=) |
| IL (2) | IL189273A (https=) |
| MA (1) | MA29875B1 (https=) |
| MX (1) | MX2008003882A (https=) |
| NO (1) | NO345131B1 (https=) |
| NZ (3) | NZ591443A (https=) |
| PL (1) | PL1940364T5 (https=) |
| PT (1) | PT1940364E (https=) |
| SI (1) | SI1940364T2 (https=) |
| TN (1) | TNSN08136A1 (https=) |
| UA (2) | UA115861C2 (https=) |
| WO (1) | WO2007038315A2 (https=) |
| ZA (1) | ZA200802237B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060446A1 (fr) | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif |
| ES2600460T3 (es) | 2005-05-10 | 2017-02-09 | Intermune, Inc. | Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés |
| NZ591443A (en) † | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| EP2471534A1 (en) | 2006-12-18 | 2012-07-04 | Intermune, Inc. | Method of providing pirfenidone therapy to a patient |
| US20080242293A1 (en) * | 2007-04-02 | 2008-10-02 | Cequint, Inc. | System and method for providing caller id name display in wireless communications system |
| WO2008147169A2 (es) * | 2007-05-29 | 2008-12-04 | Cell Therapy Technology, S.A. De C.V. | Microemolsion conteniendo pirfenidona |
| WO2008157786A1 (en) | 2007-06-20 | 2008-12-24 | Auspex Pharmaceutical, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| EP2262501B1 (en) * | 2008-03-07 | 2014-08-13 | Solanan, Inc. | Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone |
| CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
| US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| AP2011005824A0 (en) * | 2009-01-26 | 2011-08-31 | Intermune Inc | Methods for treating acute myocardial infarctions and associated disorders. |
| AU2010226726B8 (en) | 2009-03-16 | 2014-08-14 | Pangu Biopharma Limited | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| CN101912395B (zh) * | 2010-08-12 | 2012-09-26 | 北京凯因科技股份有限公司 | 一种含吡非尼酮的药物组合物及其制备方法 |
| WO2012106382A1 (en) | 2011-01-31 | 2012-08-09 | Genoa Pharmaceuticals, Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| JP2014507474A (ja) | 2011-03-08 | 2014-03-27 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換ｎ−アリールピリジノン |
| CN102670632A (zh) * | 2011-03-12 | 2012-09-19 | 赵海静 | 吡非尼酮在抑制皮肤瘢痕形成的医药用途 |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| US20130149383A1 (en) * | 2011-12-12 | 2013-06-13 | Cory Berkland | Sustained release particle formulations of guaifenesin |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| EP2968292A4 (en) | 2013-03-15 | 2016-11-23 | Intermune Inc | METHOD FOR IMPROVING MICROVASCULAR INTEGRITY |
| ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| MY194303A (en) * | 2013-12-13 | 2022-11-27 | Novartis Ag | Pharmaceutical dosage forms |
| AU2015204558B2 (en) | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| JP6420459B2 (ja) * | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー，リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
| JPWO2016059815A1 (ja) * | 2014-10-15 | 2017-08-03 | 安良太 吾妻 | 癌化学予防薬 |
| CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| TWI745396B (zh) * | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
| KR102051559B1 (ko) * | 2016-12-09 | 2019-12-05 | 재단법인 아산사회복지재단 | 섬유증의 진단 또는 치료를 위한 스테아르산의 용도 |
| KR20180100869A (ko) * | 2017-03-02 | 2018-09-12 | 영진약품 주식회사 | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 |
| CA3060514A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| ES2900457T3 (es) * | 2018-01-12 | 2022-03-17 | Tiefenbacher Alfred E Gmbh & Co Kg | Formulación de comprimidos y cápsulas que contienen pirfenidona |
| US20210205253A1 (en) * | 2018-05-31 | 2021-07-08 | The Asan Foundation | Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis |
| WO2020003107A1 (en) * | 2018-06-29 | 2020-01-02 | Zenvision Pharma Llp | Low dose oral pharmaceutical composition of pirfenidone or salt thereof |
| WO2020115774A1 (en) | 2018-12-06 | 2020-06-11 | Cipla Limited | High drug load extended release formulations |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
| KR20220137699A (ko) * | 2020-02-06 | 2022-10-12 | 가부시키가이샤 리보믹 | 망막하 고반사 병소 또는 망막하 고반사 병소를 수반하는 망막 질환의 치료제 |
| CA3171622A1 (en) * | 2020-03-13 | 2021-09-16 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| US20230135671A1 (en) | 2020-04-01 | 2023-05-04 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
| CA3175526A1 (en) * | 2020-04-14 | 2021-10-21 | Estuardo Aguilar-Cordova | Pirfenidone for coronavirus treatment |
| CN115666533B (zh) * | 2020-04-22 | 2024-08-09 | 永进药品工业株式会社 | 具有改善的安全性和稳定性的含吡非尼酮的肠溶包衣制剂及其制备方法 |
| WO2022158956A1 (ko) | 2021-01-25 | 2022-07-28 | 주식회사 나이벡 | 섬유화 예방 및 치료용 펩타이드 |
| CN117224429B (zh) * | 2023-11-15 | 2024-02-06 | 南京天纵易康生物科技股份有限公司 | 一种含羟乙基纤维素作为崩解剂的烟酰胺/肽类固液分离护肤组合物及其制备方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
| CA1049411A (en) † | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
| US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
| JPH02215719A (ja) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
| US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US5518729A (en) * | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| JPH08510251A (ja) * | 1993-05-07 | 1996-10-29 | ビー マーゴリン、ソロモン | 線維症の病変の修復と予防のための組成物および方法 |
| US5591766A (en) * | 1993-12-03 | 1997-01-07 | Cheil Foods & Chemicals, Inc. | Solid oral formulations of pyridone carboxylic acids |
| US6090822A (en) * | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
| BR9610480A (pt) * | 1995-09-19 | 1999-03-16 | Solomon Begelfor Margolin | Inibição do fator alfa de necrose tumoral |
| US5962478A (en) * | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
| CA2403594A1 (en) * | 2000-03-27 | 2002-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Granules having good taking property |
| WO2002060446A1 (fr) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif |
| WO2002087549A1 (fr) * | 2001-04-25 | 2002-11-07 | Taisho Pharmaceutical Co., Ltd. | Comprimes a liberation prolongee du type a unites multiples |
| US7007089B2 (en) * | 2001-06-06 | 2006-02-28 | Akarnai Technologies, Inc. | Content delivery network map generation using passive measurement data |
| US7512702B1 (en) * | 2002-03-19 | 2009-03-31 | Cisco Technology, Inc. | Method and apparatus providing highly scalable server load balancing |
| US7139840B1 (en) * | 2002-06-14 | 2006-11-21 | Cisco Technology, Inc. | Methods and apparatus for providing multiple server address translation |
| AU2003262811A1 (en) | 2002-08-27 | 2004-03-19 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| EP1551369A4 (en) * | 2002-08-28 | 2007-05-09 | Intermune Inc | COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES |
| US7159034B1 (en) * | 2003-03-03 | 2007-01-02 | Novell, Inc. | System broadcasting ARP request from a server using a different IP address to balance incoming traffic load from clients via different network interface cards |
| UA80872C2 (uk) * | 2003-03-31 | 2007-11-12 | Пліва-Лахема А.С. | Фармацевтична композиція, що містить як активну речовину платиновий комплекс, і спосіб її виготовлення |
| US20050008691A1 (en) * | 2003-05-14 | 2005-01-13 | Arturo Siles Ortega | Bicalutamide compositions |
| CA2525647A1 (en) | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| WO2004103296A2 (en) | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| WO2005004763A1 (en) * | 2003-07-01 | 2005-01-20 | Pharmacia & Upjohn Company Llc. | Diffusion layer modulated solids |
| US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| CN100358872C (zh) | 2003-11-14 | 2008-01-02 | 上海睿星基因技术有限公司 | 吡啶酮衍生物及其应用 |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8642079B2 (en) * | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
| US7584435B2 (en) * | 2004-03-03 | 2009-09-01 | Omniture, Inc. | Web usage overlays for third-party web plug-in content |
| MX2008001166A (es) * | 2005-07-25 | 2008-03-18 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
-
2005
- 2005-09-22 NZ NZ591443A patent/NZ591443A/xx not_active IP Right Cessation
-
2006
- 2006-09-22 CN CN2013103433683A patent/CN103393607A/zh active Pending
- 2006-09-22 CA CA2762013A patent/CA2762013C/en active Active
- 2006-09-22 ES ES06815221T patent/ES2496144T5/es active Active
- 2006-09-22 AP AP2012006231A patent/AP2012006231A0/xx unknown
- 2006-09-22 PL PL06815221.4T patent/PL1940364T5/pl unknown
- 2006-09-22 SI SI200631819T patent/SI1940364T2/sl unknown
- 2006-09-22 AU AU2006295440A patent/AU2006295440B2/en not_active Revoked
- 2006-09-22 KR KR1020087006806A patent/KR20080046673A/ko not_active Ceased
- 2006-09-22 CN CNA2006800348742A patent/CN101267810A/zh active Pending
- 2006-09-22 KR KR1020147004496A patent/KR101675651B1/ko active Active
- 2006-09-22 EP EP06815221.4A patent/EP1940364B2/en active Active
- 2006-09-22 EP EP11007850A patent/EP2431025A1/en not_active Withdrawn
- 2006-09-22 NZ NZ565957A patent/NZ565957A/en not_active IP Right Cessation
- 2006-09-22 CN CN201410057564.9A patent/CN103735530A/zh active Pending
- 2006-09-22 GE GEAP200610558A patent/GEP20115303B/en unknown
- 2006-09-22 WO PCT/US2006/037057 patent/WO2007038315A2/en not_active Ceased
- 2006-09-22 KR KR1020137022095A patent/KR101645069B1/ko active Active
- 2006-09-22 DK DK06815221.4T patent/DK1940364T4/da active
- 2006-09-22 CU CU20080043A patent/CU20080043A7/es unknown
- 2006-09-22 MX MX2008003882A patent/MX2008003882A/es active IP Right Grant
- 2006-09-22 UA UAA201203869A patent/UA115861C2/uk unknown
- 2006-09-22 ZA ZA200802237A patent/ZA200802237B/xx unknown
- 2006-09-22 AP AP2008004390A patent/AP2655A/xx active
- 2006-09-22 PT PT68152214T patent/PT1940364E/pt unknown
- 2006-09-22 CA CA2620380A patent/CA2620380C/en active Active
- 2006-09-22 EA EA200800881A patent/EA030093B1/ru active Protection Beyond IP Right Term
- 2006-09-22 US US12/067,712 patent/US7988994B2/en active Active
- 2006-09-22 BR BRPI0616324-6A patent/BRPI0616324A2/pt not_active Application Discontinuation
- 2006-09-22 JP JP2008532431A patent/JP5837732B2/ja active Active
- 2006-09-22 UA UAA200805048A patent/UA99433C2/ru unknown
- 2006-09-22 NZ NZ600129A patent/NZ600129A/en not_active IP Right Cessation
-
2008
- 2008-02-04 IL IL189273A patent/IL189273A/en active IP Right Grant
- 2008-02-12 NO NO20080759A patent/NO345131B1/no unknown
- 2008-03-19 TN TNP2008000136A patent/TNSN08136A1/en unknown
- 2008-04-17 MA MA30855A patent/MA29875B1/fr unknown
- 2008-04-22 EC EC2008008394A patent/ECSP088394A/es unknown
-
2009
- 2009-04-17 US US12/426,182 patent/US7767225B2/en active Active
-
2011
- 2011-04-05 AU AU2011201520A patent/AU2011201520B2/en not_active Revoked
- 2011-06-16 US US13/162,048 patent/US8383150B2/en active Active
-
2012
- 2012-08-17 JP JP2012180913A patent/JP5715101B2/ja active Active
-
2013
- 2013-02-25 US US13/776,079 patent/US8753679B2/en active Active
-
2014
- 2014-05-07 US US14/271,720 patent/US20140242159A1/en not_active Abandoned
- 2014-06-24 JP JP2014129551A patent/JP2014169341A/ja active Pending
- 2014-09-10 CY CY20141100731T patent/CY1115544T1/el unknown
-
2015
- 2015-07-09 IL IL239868A patent/IL239868A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115544T1 (el) | Σκευασμα καψουλων πιρφενιδονης και αποδεκτων φαρμακευτικως εκδοχων | |
| NO20053224D0 (no) | Patient controlled drug administration device. | |
| CY1125621T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση των διαταραχων ανωμαλης, ακουσιας κινησης | |
| CY1121593T1 (el) | Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων | |
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| CY1110606T1 (el) | Χρηση των ανταγωνιστων της il-23 και il-17 για τη θεραπεια της αυτοανοσης οφθαλμικης φλεγμονωδους νοσου | |
| ITMI20041317A1 (it) | Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento | |
| DK1957110T3 (da) | Fremgangsmåde til fremstilling af tygbare doseringsformer til lægemiddeladministration og produkter dermed | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| EP4324521A3 (en) | Treatment of fabry disease in ert-naive and ert-experienced patients | |
| EA201590797A1 (ru) | Препараты с модифицированным высвобождением опрозомиба | |
| DK1546127T3 (da) | Nye pyrimidinamidderivater og anvendelse deraf | |
| CY1121921T1 (el) | Φαρμακευτικα σκευασματα | |
| NO20055173L (no) | Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel | |
| NO20050569D0 (no) | Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette | |
| NO20082986L (no) | Nye, acylisk substituerte furopyrimidinderivater og anvendelse derav for behandling av kardiovaskulaere lidelser | |
| JP2018090572A5 (https=) | ||
| EP4159104A4 (en) | MEDICAL CAPSULE | |
| IL286646A (en) | Compositions, devices and methods for treating fabry disease | |
| NO20081559L (no) | Kit for parenteral administrering av medikamenter | |
| ATE477805T1 (de) | 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität | |
| IL217519A (en) | Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders | |
| CY1111608T1 (el) | Σκευασμα φλουπιρτινης για τη θεραπεια νευροεκφυλιστικων νοσων του οπτικου συστηματος και του σακχαρωδη διαβητη | |
| EA200602154A1 (ru) | Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5 | |
| NO20075508L (no) | Stannsoporfinpreparater og administrering |